Quantum BioPharma, Thermo Fisher Partner on Phase 2 Multiple Sclerosis Trial
MT newswire2026/10/06 10:4406:44 AM EDT, 10/06/2026 (MT Newswires) -- Quantum BioPharma (QNTM) has signed a Study Start-Up Agreement with Thermo Fisher Scientific's (TMO) clinical research business to support the implementation of its Phase 2 Lucid-21-302, or Lucid-MS, trial for multiple sclerosis, the company said Tuesday. The agreement follows US Food and Drug Administration clearance for the randomized, double-blind, placebo-controlled trial, which will assess the efficacy, safety, and tolerability of Lucid-MS in patients with progressive multiple sclerosis. Thermo Fisher will support study start-up and related clinical research, with the trial evaluating clinical and radiological measures of disease progression, it added.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Crypto prices
More
